| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 20.75▲ | 20.83▼ | 20.76▲ | 19.93▲ | 19.44▲ |
| MA10 | 20.90▼ | 20.66▲ | 20.39▲ | 19.38▲ | 16.82▲ |
| MA20 | 20.85▼ | 20.26▲ | 19.90▲ | 19.21▲ | 12.95▲ |
| MA50 | 20.61▲ | 19.82▲ | 19.59▲ | 15.71▲ | 9.56▲ |
| MA100 | 20.03▲ | 19.56▲ | 19.18▲ | 12.30▲ | 8.46▲ |
| MA200 | 19.81▲ | 19.16▲ | 19.58▲ | 9.88▲ | 9.23▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.049▼ | 0.059▲ | 0.131▲ | -0.154▼ | 0.880▲ |
| RSI | 52.581▲ | 61.843▲ | 64.613▲ | 59.883▲ | 66.038▲ |
| STOCH | 14.293▼ | 77.457 | 84.357▲ | 76.948 | 58.410 |
| WILL %R | -62.963 | -21.656▲ | -16.038▲ | -10.828▲ | -40.542 |
| CCI | -69.460 | 64.116 | 85.524 | 204.699▲ | 76.192 |
|
Thursday, July 23, 2026 02:56 AM
WSW, NY, July 23rd, 2026, FinanceWireNuvectis Pharma (NASDAQ: NVCT) announced this morning that ciprocopan (NXP100) has been ...
|
|
Wednesday, July 08, 2026 10:35 PM
In June, Nuvectis Pharma (NASDAQ: NVCT) signed a deal that took it from a single-drug oncology company to the owner of one of the more closely watched assets in rare-disease medicine: NXP100, a once-a ...
|
|
Wednesday, July 08, 2026 05:00 PM
Detailed price information for Nuvectis Pharma Inc (NVCT-Q) from The Globe and Mail including charting and trades.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 29/07/26 | 19.88 | 21.16 | 19.88 | 20.82 | 272,825 |
| 28/07/26 | 19.85 | 20.00 | 19.00 | 19.82 | 195,509 |
| 27/07/26 | 19.37 | 20.00 | 19.01 | 19.54 | 145,810 |
| 24/07/26 | 20.19 | 20.20 | 19.04 | 19.31 | 245,631 |
| 23/07/26 | 19.29 | 20.20 | 18.76 | 20.15 | 325,540 |
| 22/07/26 | 19.10 | 19.75 | 19.01 | 19.29 | 157,150 |
| 21/07/26 | 18.10 | 19.70 | 18.10 | 19.08 | 198,383 |
| 20/07/26 | 19.11 | 20.025 | 18.02 | 18.03 | 337,678 |
| 17/07/26 | 18.30 | 19.21 | 18.0407 | 19.14 | 330,800 |
| 16/07/26 | 19.56 | 19.97 | 18.38 | 18.60 | 341,430 |
|
|
||||
|
|
||||
|
|